Chardan Capital Has Strong Estimate for COYA FY2025 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Chardan Capital increased their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the company will earn ($1.03) per share for the year, up from their prior estimate of ($1.26). Chardan Capital has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Separately, D. Boral Capital restated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Thursday.

Coya Therapeutics Stock Down 4.8 %

NASDAQ COYA opened at $6.56 on Thursday. The stock’s 50-day moving average price is $6.43 and its 200-day moving average price is $6.51. The company has a market capitalization of $109.72 million, a P/E ratio of -10.09 and a beta of 0.31. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million.

Institutional Trading of Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in COYA. Tower Research Capital LLC TRC boosted its stake in Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after purchasing an additional 4,777 shares during the period. XTX Topco Ltd bought a new stake in shares of Coya Therapeutics during the fourth quarter valued at approximately $59,000. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics in the fourth quarter worth $74,000. Northern Trust Corp boosted its position in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after acquiring an additional 3,099 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in Coya Therapeutics during the fourth quarter valued at $401,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.